
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) October 7, 2011

FLUIDIGM CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34180
(Commission
File Number)

77-0513190
(IRS Employer
Identification No.)

7000 Shoreline Court, Suite 100
South San Francisco, California 94080
(Address of principal executive offices, including zip code)

(650) 266-6000
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02 Results of Operations and Financial Condition

On October 7, 2011, Fluidigm Corporation issued a press release affirming its previously disclosed 2011 financial outlook. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits**(d) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Fluidigm Corporation Press Release dated October 7, 2011

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FLUIDIGM CORPORATION

By: /s/ Vikram Jog

Vikram Jog
Chief Financial Officer

Date: October 7, 2011

EXHIBIT INDEX

Exhibit No.

Description

99.1 Fluidigm Corporation Press Release dated October 7, 2011

FLUIDIGM AFFIRMS 2011 FINANCIAL OUTLOOK

SOUTH SAN FRANCISCO, Calif. – October 7, 2011 – Fluidigm Corporation (NASDAQ:FLDM) today announced it is affirming its previously disclosed 2011 financial outlook.

In its August 9, 2011 earnings release, Fluidigm disclosed that for the full year 2011, year-over-year product revenue growth was projected to be at the high end of a range of 27% to 30% and revenue from grants and collaborations was projected to be around \$2.0 million. Nothing has come to Fluidigm's attention that would cause it to change such guidance.

Fluidigm has elected to make this announcement given concerns regarding research funding levels, overall market conditions and recent announcements by other life science tools companies. Fluidigm does not expect to make future announcements regarding its financial outlook outside of its regularly-scheduled quarterly earnings calls. Fluidigm will conduct its next quarterly earnings call in early November, when it will present more detailed financial information and a business update.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements relating to current estimates of 2011 revenue growth and revenue from grants and collaborations. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that could materially affect future results include, but are not limited to, risks relating to market acceptance of our products, the potential for quarterly variations in our operating results, our ability to successfully launch new products and applications, competition in our primary markets, variability in our sales cycle, our need to expand our sales, marketing and distribution capabilities, research funding levels, adverse developments in specific geographic markets and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Fluidigm's business and operating results are contained in our Annual Report on Form 10-K for the year ended December 31, 2010, Fluidigm's subsequent Quarterly Reports on Form 10-Q and Fluidigm's other filings with the Securities and Exchange Commission. These forward looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements.

About Fluidigm

Fluidigm (NASDAQ: FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm's proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits, or chips, and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including nine different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.

####

CONTACT:

Howard High
Fluidigm Corporation

650.266.6081 (office)
510.786.7378 (mobile)
howard.high@fluidigm.com

William (Bill) Craumer – Investors
Fluidigm Corporation
650.266.6188
bill.craumer@fluidigm.com